NEWS

Press Releases

Media Coverage

Additional Partnerships

11/15/2017
- Genomic Sequencing
Tempus Announces Latest Immunotherapy Project

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, along with Georgetown Lombardi Comprehensive Cancer Center, in Washington, D.C., and John Theurer Cancer Center at Hackensack Meridian HealthHackensack University Medical Center announce a new...
11/01/2017
- Clinical Trials
- Genomic Sequencing
Tempus and Sanford Health Collaborate on Personalized Medicine Initiative

Tempus, a rapidly-growing technology company focused on collecting and integrating molecular and clinical data and Sanford Health, one of the largest health system in the nation will collaborate to identify targeted therapies and clinical trials for breast cancer patients. As part of the collaboration, Sanford Health will collect...
10/19/2017
Tempus Unveils Tempus xT, 595 Gene Panel Aimed at Empowering Data-Driven Cancer Care

Tempus today announced the launch of its new comprehensive genomic sequencing panel, Tempus xT, which analyzes 595 genes relevant to the diagnosis, prognosis and therapeutic targeting of cancer. The panel will sequence a patient’s tumor DNA and RNA, as well as a matched normal blood or saliva to...
09/28/2017
- Clinical Trials
- Genomic Sequencing
Tempus and the OHSU Knight Cancer Institute Collaborating on Personalized Medicine Data Initiative

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and the Knight Cancer Institute at OHSU in Portland, Oregon, have announced a new collaboration aimed at improving outcomes for breast, pancreatic, and prostate cancer patients. ...
09/25/2017
- Genomic Sequencing
Tempus Announces $130M Raised

Tempus announced today that it closed a $70M, Series C, round of venture funding co-led by New Enterprise Associates (NEA) and Revolution Growth. This latest round brings the two-year-old company’s total funding to $130M. Tempus has spent the last two years building a series of data pipelines...
09/14/2017
- Clinical Trials
- Genomic Sequencing
Tempus and Cleveland Clinic Collaborate on Personalized Medicine Initiative

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Cleveland Clinic Taussig Cancer Institute will collaborate on a precision medicine initiative aimed at improving outcomes for patients diagnosed with cancer. As part of the...
08/31/2017
- Clinical Trials
- Genomic Sequencing
Tempus and University of California Davis Comprehensive Cancer Center Announce Personalized Medicine Partnership for Cancer Patients

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data and University of California Davis Comprehensive Cancer Center are collaborating on a precision medicine partnership to advance clinical care with Next Generation Sequencing analysis, focused initially...
08/17/2017
- Clinical Trials
- Genomic Sequencing
Tempus Selected as Sequencing and Analytics Provider by the Prostate Cancer Clinical Trials Consortium forPhase II Clinical Trial

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data announced today that it was selected by the Prostate Cancer Clinical Trials Consortium (PCCTC) to serve as a partner for its phase II clinical trial focused...
07/21/2017
- Genomic Sequencing
Tempus and Rush University Medical Center Partnering to Expand Hospital’s First Biobank

Tempus, a technology company focused on helping doctors personalize cancer care by collecting, sorting and analyzing clinical and molecular data, and Rush University Medical Center (Rush) announce their second collaboration aimed at accelerating research and treatment options for patients battling cancer. Tempus will help Rush expand and operationalize...
07/20/2017
Tempus xO Assay Validation

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and integrating molecular and clinical data, today announced its Tempus xO assay has been validated with clinically actionable variance. The Tempus xO assay combines a 1,711 gene somatic and germline DNA sequencing panel with RNA-sequencing. It...

1 2 3 4 5 6 7 8 9 10 11 12 13 14